obeposition.blogspot.com
Obesity: September 2010
http://obeposition.blogspot.com/2010_09_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. Rhythm Pharmaceuticals : RM-493 Reverses Obesity a. Abbott : Statement on the FDA Advisory Committee R. Crospon : EndoFLIP system presented at Internatio. Orexigen Therapeutics and Takeda Pharmaceutical : . NeuroSearch : Interim report for H1 2010 - Tesofe. Tuesday, September 28, 2010. Monday, September 20, 2010.
obeposition.blogspot.com
Obesity: May 2011
http://obeposition.blogspot.com/2011_05_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. Archimedes, Inc. and FDA : Collaboration to Evalua. GlaxoSmithKline : non-core OTC products to be dive. Tuesday, May 24, 2011. Archimedes, Inc. and FDA : Collaboration to Evaluate the Clinical Risks and Benefits of Weight Loss Medications. 8212; Archimedes Inc. Publié par Benjamin de Bélizal. Identified the non...
obeposition.blogspot.com
Obesity: October 2010
http://obeposition.blogspot.com/2010_10_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. Johnson and Johnson [JNJ] : Therapeutic Benefits o. Weight Watchers and Merck Collaborate to Help Phys. DeCODE : Not only Size Matters: Genetic Megastudie. Bionovo : NIH Grant to Develop Drugs for the Treat. Tuesday, October 26, 2010. Université du Québec à Montréal (UQAM). And Analysis Group, Inc. Shows that c...
obeposition.blogspot.com
Obesity: August 2011
http://obeposition.blogspot.com/2011_08_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. BioRestorative Therapies : License Agreement with . GI Dynamics : Australian TGA Approval For the Endo. Thursday, August 25, 2011. BioRestorative Therapies : License Agreement with University of Utah to Obtain Adipose (fat) Tissue for its Thermostem Program to Treat Obesity and . The agreement marks the beginni...
obeposition.blogspot.com
Obesity: July 2011
http://obeposition.blogspot.com/2011_07_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. Unigene : Positive Advanced Preclinical Data for U. AMRI : Successful Completion of Phase I Clinical S. Tuesday, July 19, 2011. Unigene : Positive Advanced Preclinical Data for UGP281 a Potent, Orally Delivered Anorexigenic Peptide. Unigene Laboratories, Inc. (OTCBB: UGNE). Titled: "Preclinical Studies with UGP...
obeposition.blogspot.com
Obesity: January 2012
http://obeposition.blogspot.com/2012_01_01_archive.html
Blog, news, companies, Body Mass Index, BMI, weight loss, obese, adjustable gastric lap-band surgery, Weight Management, Nutritional, overweight. Pharmaceuticals Search Engine [selected websites]. Arena Pharmaceuticals and Eisai : FDA Accepts Resu. Ember Therapeutics : Nature Publication of Brown F. Isis : Phase 1 Clinical Trial of ISIS-FGFR4Rx a Pe. Monday, January 30, 2012. Arena Pharmaceuticals and Eisai : FDA Accepts Resubmission of Lorcaserin New Drug Application. PDF] Eisai's Press Release. A compa...
alzposition.blogspot.com
Alzheimer: June 2011
http://alzposition.blogspot.com/2011_06_01_archive.html
Blog, news and companies for neurodegenerative diseases, disorders, alzheimer, screening test, brain, memory, dementia, diagnostic, treatment, vaccine, neurologic, Neuroscience, cognitive deficits,Alzheimer's disease Assessment Scale. Pharmaceuticals Search Engine [selected websites]. YUMA THERAPEUTICS AWARDED A RESEARCH GRANT BY THE . Axxam : Research Grant by the Alzheimer’s Drug Dis. Clarimedix : Treatment Targets Alzheimers Symptom. Mylan : Approval for Generic Version of Aricept T. June, 22nd 2011 -...
alzposition.blogspot.com
Alzheimer: October 2011
http://alzposition.blogspot.com/2011_10_01_archive.html
Blog, news and companies for neurodegenerative diseases, disorders, alzheimer, screening test, brain, memory, dementia, diagnostic, treatment, vaccine, neurologic, Neuroscience, cognitive deficits,Alzheimer's disease Assessment Scale. Pharmaceuticals Search Engine [selected websites]. Transition Therapeutics : Publication of ELND005 P. Brainsway : Positive Interim Results in Alzheimer. Wednesday, October 19, 2011. September 27th, 2011 - Transition Therapeutics Inc. Publié par Benjamin de Bélizal. Is plea...
alzposition.blogspot.com
Alzheimer: Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease
http://alzposition.blogspot.com/2015/04/alzheon-alz-801-alzheimer-disease-phase.html
Blog, news and companies for neurodegenerative diseases, disorders, alzheimer, screening test, brain, memory, dementia, diagnostic, treatment, vaccine, neurologic, Neuroscience, cognitive deficits,Alzheimer's disease Assessment Scale. Pharmaceuticals Search Engine [selected websites]. Alzheon Announces Phase 1 Results of ALZ-801, a Fi. Tuesday, April 14, 2015. Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease.
alzposition.blogspot.com
Alzheimer: April 2015
http://alzposition.blogspot.com/2015_04_01_archive.html
Blog, news and companies for neurodegenerative diseases, disorders, alzheimer, screening test, brain, memory, dementia, diagnostic, treatment, vaccine, neurologic, Neuroscience, cognitive deficits,Alzheimer's disease Assessment Scale. Pharmaceuticals Search Engine [selected websites]. Alzheon Announces Phase 1 Results of ALZ-801, a Fi. Tuesday, April 14, 2015. Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease.